Antiviral Treatment Duration for Viral Encephalitis
For HSV encephalitis in adults, treat with intravenous acyclovir 10 mg/kg every 8 hours for 14-21 days; for children aged 3 months to 12 years, use a minimum of 21 days due to higher relapse rates up to 29%. 12
HSV Encephalitis: The Primary Treatable Cause
Adults
- Standard duration: 14-21 days of IV acyclovir at 10 mg/kg every 8 hours (with normal renal function) 1
- Earlier treatment initiation dramatically improves outcomes—mortality drops to 8% when started within 4 days of symptom onset versus 28% overall 1
- Consider repeat lumbar puncture at 14-21 days to confirm CSF HSV PCR negativity, particularly in severe disease, immunocompromised patients, or those with previous relapses 22
- If CSF remains PCR-positive at end of treatment, continue acyclovir with weekly CSF PCR monitoring until negative 22
Children (3 months - 12 years)
- Minimum 21 days of IV acyclovir before considering stopping treatment 22
- This age group has the highest relapse risk (26-29%), especially with treatment <14 days 22
- Repeat LP at 21 days to confirm CSF PCR negativity 2
Neonates
- Higher dosing required: 20 mg/kg IV every 8 hours for 21 days 1
- This regimen reduced mortality to 5% with ~40% of survivors developing normally 1
- Relapse rate ~8% with lower doses (10 mg/kg for 10 days), but not documented with the higher 21-day regimen 1
Varicella-Zoster Virus (VZV) Encephalitis
While no randomized trials establish optimal duration, treat with IV acyclovir 10-15 mg/kg every 8 hours for 10-21 days based on clinical severity and immune status 34. Immunocompromised patients typically require longer courses and may need continuation until CSF clears.
West Nile Virus and Other Non-Herpetic Viral Encephalitis
No specific antiviral therapy exists—management is supportive 4. Do not continue empiric acyclovir once HSV/VZV are excluded.
Influenza Encephalitis
Oseltamivir should be initiated within 48 hours of symptom onset for severe influenza-related CNS disease 5. Standard treatment duration is 5 days, though severe cases may warrant longer courses.
Adjustments for Immunocompromised Patients
- Extend treatment duration beyond standard 14-21 days 22
- Mandatory repeat CSF analysis to document viral clearance before stopping therapy 2
- Continue acyclovir until CSF PCR becomes negative, checking weekly 22
- Higher risk of relapse and persistent viral replication 2
Critical Monitoring Parameters
When to Continue Beyond Standard Duration:
- Persistent positive CSF HSV PCR at 14-21 days 22
- Severe disease (Glasgow Coma Score <6) 1
- Immunocompromised status 22
- Poor clinical response to initial therapy 2
When Empiric Acyclovir Can Be Safely Stopped (HSV PCR-negative):
In immunocompetent patients, stop if:
- Alternative diagnosis confirmed, OR
- HSV PCR negative on two occasions 24-48 hours apart AND MRI (>72 hours post-symptom onset) not characteristic for HSV, OR
- Single negative HSV PCR >72 hours after symptom onset WITH normal consciousness, normal MRI (>72 hours post-onset), AND CSF WBC <5 × 10⁶/L 222
Important Safety Considerations
Acyclovir nephrotoxicity occurs in up to 20% of patients, typically after 4 days of IV therapy 22. Mitigate risk by:
- Maintaining adequate hydration throughout treatment
- Monitoring renal function regularly
- Dose-adjusting for pre-existing renal impairment
- Recognizing that crystalluria and obstructive nephropathy are reversible 2
Common Pitfalls to Avoid
- Stopping treatment at 10 days—this outdated duration from original trials is associated with unacceptable relapse rates 22
- Discontinuing acyclovir based on single early negative CSF PCR (<72 hours)—PCR can be falsely negative early in disease 22
- Using oral acyclovir for CNS disease—inadequate CSF penetration makes it unsuitable for encephalitis treatment 22
- Undertreating children aged 3 months-12 years—this group requires the full 21 days minimum 22